Publications by authors named "Bryce Barr"
New therapies for immunoglobulin A nephropathy: what's the standard of care in 2023?
Curr Opin Nephrol Hypertens
May 2024
Article Synopsis
- Immunoglobulin A nephropathy (IgAN) is a major cause of kidney failure and, until recently, had limited treatment options.
- New clinical trials, such as the TESTING trial, show promise in using glucocorticoids and other therapies to slow kidney disease progression and improve safety.
- The challenge now lies in selecting the most effective treatment for individual patients, as various new therapies are becoming available for this condition.
Background: Glomerulonephritis (GN) represents a common cause of chronic kidney disease, and treatment to slow or prevent progression of GN is associated with significant morbidity. Large patient registries have improved the understanding of risk stratification, treatment selection, and definitions of treatment response in GN, but can be resource-intensive, with incomplete patient capture.
Objective: To describe the creation of a comprehensive clinicopathologic registry for all patients undergoing kidney biopsy in Manitoba, using natural language processing software for data extraction from pathology reports, as well as to describe cohort characteristics and outcomes.
Background: Guidelines recommend that non-steroidal anti-inflammatory drugs (NSAIDs) be avoided in kidney transplant recipients due to potential nephrotoxicity. It is unclear whether physicians are following these recommendations.
Methods: We conducted a retrospective cohort study of adult kidney transplant recipients from 2008 to 2017 in Alberta, Canada.